MiMedx's Wound Care Business Is Cratering and It Just Bet $350 Million on an Acquisition — Is This a Lifeline or a Gamble?

Shares of MiMedx Group tumbled 10.9% to $3.77 in after-hours trading on July 29 after the regenerative-medicine company paired a bruising second quarter with a surprise deal to buy Sanara MedTech. The combination of shrinking revenue, compressed margins, and a debt-financed acquisition raises a pointed question: can management stabilize the core business while digesting a major deal?

Medicare's Reimbursement Overhaul Is Gutting the Biggest Revenue Line. Q2 net sales fell 35% year-over-year to $64 million, dragged down by a 61% collapse in wound-care revenue tied to Medicare reimbursement changes that took effect January 1.

Gross profit dropped to $44 million from $80 million a year ago, and gross margin slid to 69% from 81%, driven by lower prices the government now allows for wound products. This isn't a one-quarter blip — Q1 showed a nearly identical pattern, with a 60% wound decline and 33% overall revenue drop.

Surgery Is Growing, but Not Fast Enough to Fill the Hole. CEO Joseph Capper highlighted 15% year-over-year surgical revenue growth across sheet and particulate products, calling it "a meaningful, long-term growth opportunity." But surgery is still roughly half the business. A 15% rise on one side cannot offset a 61% plunge on the other — total revenue is still shrinking by double digits.

A $350 Million Deal Adds Debt at the Worst Possible Time. MiMedx agreed to buy Sanara MedTech at $35 per share — a total enterprise value of roughly $350 million and a 46% premium to Sanara's 30-day average stock price.

The cash portion will be funded partly through a new $300 million term loan from Hayfin Capital Management. For a company whose cash position was $119 million net of debt as of June 30 , taking on that kind of leverage while revenue is falling sharply makes integration risk a real concern.

Management Says the Worst Is Over — the Market Isn't Buying It. Executives said they "took swift action to right-size" expenses and reiterated full-year 2026 sales guidance of $260–$290 million.

An earlier restructuring targeted $40 million in annual cost savings. Yet the stock's after-hours slide suggests investors see reaffirmed guidance and cost cuts as insufficient to offset a massive revenue decline and the risks of bolting on an acquisition mid-crisis.